PRKN and Parkinson disease: In mouse models of SCA2, this approach has been shown to significantly reduce ATXN2 mRNA and protein levels and attenuate electrophysiological abnormalities [47]。Parkin mutations are associated with most familial early-onset Parkinson's disease.